A daily medication for high blood pressure could be replaced by an injection twice a year, if Queen Mary University and Barts Health NHS Trust succeed in their trail to investigate if an injection-based drug - Zilebesiran - could inhibit the production of a protein called angiotensinogen (AGT).
Scientists are to trial a world-first drug to treat high blood pressure that can be given by injection twice a year.
Professor Sir Nilesh Samani, medical director, British Heart Foundation, said: "This exciting trial could lead to good news for the millions of people across the UK with high blood pressure, many of whom need to take daily medication to lower their risk of heart attacks and strokes.
"The study will determine whether an injection given twice a year lowers blood pressure sufficiently over a prolonged period.
"If this proves to be the case, it may provide an alternative to taking daily pills for some patients."
A study by scientists in a UK university has shown the scale of the prevalence of a condition that can lead to various cardiometabolic diseases.
The study published in the Annals of Internal Medicine journal on Tuesday (January 4) has prompted calls for changes to healthcare policy after researchers revealed, for the first time, the scale of the impact of the condition associated with benign tumours that can lead to type 2 diabetes and high blood pressure.
Up to 10 per cent of adults have a benign tumour, or lump, known as an 'adrenal incidentaloma' in their adrenal glands which can be associated with the overproduction of hormones including the stress steroid hormone cortisol that can lead to type 2 diabetes and high blood pressure.
Previous small studies suggested that one in three adrenal incidentalomas produce excess cortisol, a condition called mild autonomous cortisol secretion (MACS).
An international research team led by the University of Birmingham carried out the largest ever prospective study of over 1,305 patients with adrenal incidentalomas to assess their risk of high blood pressure and type 2 diabetes and their cortisol production by comparing patients with and without MACS.
The National Health Service (NHS) on Monday launched a new national campaign to find the 'missing millions' who could be living with undiagnosed high
blood pressure, often described as a 'silent killer'.
People are being warned that the condition rarely has any symptoms and it can lead to fatal heart attacks, strokes, kidney disease and vascular dementia, if
left untreated.
According to the NHS, high blood pressure affects an estimated 32 per cent of adults and approximately three in 10 of these remain undiagnosed, equating to
4.2 million people in England.
The NHS has expanded blood pressure checks in community pharmacies to include 2.5 million more tests as part of the Pharmacy First programme.
With the 'Get Your Blood Pressure Checked' campaign, the health service is encouraging those aged 40 years and over to get a free blood pressure test at a
participating pharmacy, for which they don't need to be booked in advance.
Health Minister Andrea Leadsom expressed confidence that this new drive will help to prevent the potentially "fatal consequences" of untreated high blood
pressure. She urged people to go to their local pharmacy to get their blood pressure checked, stating that it could be a "lifesaving trip."
A new study has revealed that public trust in services provided by local pharmacies ranks highest in the UK, although confidence in the NHS has nosedived
following the pandemic.
The 2022 Edelman Trust Barometer report published on Wednesday (April 21) found that around 78 per cent of respondents trust their local pharmacies, the highest for any provider cited in the survey.
Besides, 72 per cent said pharmacists are among the most trusted to tell the truth about health matters and protect public health, almost similar to 'my doctor' (75%) and health experts (74%).
Just under half of them said the pandemic has decreased their confidence that the NHS is well-equipped in handling major health crisis. The survey also revealed that 60 per cent think they lack access to high-quality healthcare.
Britain's biotech firm Avacta Group on Monday (January 10) announced halting sales of its Covid-19 rapid antigen lateral flow test AffiDX to replace antibodies in the device and increase its ability to diagnose the Omicron variant.
The company stated that AffiDX is capable of detecting Omicron when the virus is present in high numbers in samples, but the sensitivity of the test reduces at
lower viral loads.
The performance of all rapid antigen tests came under scanner in wake of a large number of mutations in the Omicron variant.
AffiDX contains both a proprietary Affimer reagent and a commercially available antibody.
The Affimer reagent detects the Omicron variant with the same sensitivity as the Delta variant, and performance of the antibody is paired with the Affimer reagent in the test. This has been affected by the additional Omicron mutations, the firm said.
Alastair Smith, chief executive of Avacta Group, said: "Our determination to only provide high quality, high performance diagnostic tests has led us to the correct decision to pause all marketing of the AffiDX® lateral flow antigen test. We have, of course, been unable to market the product in the UK since October 2021, as the product continues to await approval under the new CTDA regulatory process.
The Royal Pharmaceutical Society (RPS) has called for urgent action to ensure wellbeing of pharmacists after the publication of its annual workforce survey.
The survey, conducted in partnership with the charity Pharmacist Support, revealed that 89 per cent of respondents were at high risk of burnout, showing ongoing high levels of workplace stress.
It stated that 57 per cent of respondents reported often being unable to take a rest break or were not offered a break at all.
Around 68 per cent noted weakening of their mental health and wellbeing due to work or study, and 33 per cent considered leaving the profession, indicating high
percent levels of disaffection.
Besides seeking urgent action to allow proper rest breaks for pharmacists, RPS has sought "governments, the NHS and employers to urgently address the workforce issues that are impacting pharmacists' wellbeing."
It said prioritising essential work, effective workforce planning and better access to information is needed.
Commenting on the survey report, RPS president Professor Claire Anderson said: "Our survey demonstrates the continued pressure on pharmacists and trainees across the workforce".
Pharmacists working in Northern Ireland think the retention fees are too high, and most would prefer to pay in instalments, if that option is available, amid
the increased living costs, a new survey has found.
97 per cent of the respondents to the survey, conducted by the Pharmacists' Defence Association (PDA) of its Northern Irish members, felt the fees were too high. Four
in five said they would opt to pay in instalments if this option were available to them in light of the challenges of significant one-off payments.
On average, the fees accounted for 23 per cent of a pharmacist's take-home pay for one month, and 98 per cent did not see any value added to their professional
standing for the sum, according to the survey.
The PDA said the respondents also reported feeling disadvantaged among their colleagues in terms of how fees are collected, with many also wondering why the
registration fee was not offset for those on maternity leave or working reduced or flexible hours.
Superdrug has announced a pay increase for newly qualified pharmacists, in a move that will see wages rise to £50,000 - ensuring that Superdrug Pharmacists
continue to receive the strongest renumeration package on the high street today.
Superdrug is also enhancing its patient experience and operational structure, with the introduction of a new role of Pharmacy Team Leader to selected pharmacy stores.
Pharmacy Team Leaders will be dispenser trained and provide a clear line of accountability for day-to-day dispensary activity including adhering to legal and
clinical frameworks whilst supporting, coaching, and developing a high-performing pharmacy team.
The role also allows Superdrug to offer a clear line of progression for talented Pharmacy Dispensers and Technicians who want to do more in their career and recognises
the valuable contribution Pharmacy Dispensers & Technicians play in community pharmacy.
In addition, the appointment of two new Heads of Pharmacy Operations sees the high street retailer driving and improving Superdrug's pharmacy performance to offer the
best possible care for patients. Craig Watt, Pharmacist and previously Area Manager, has been appointed to Head of Pharmacy Operations North and will be responsible
for the operation of Superdrug's central distribution hub serving its e-pharmacy and Online Dr team.
The Pharmaceutical Services Negotiating Committee (PSNC) has raised concerns over the impact that high medicine price rises are having on contractor.
Recently, the Department of Health and Social Care (DHSC) has granted the final list of price concessions for December 2022. The latest additions bring the total
number of concessionary prices granted for the month of December to 198, surpassing the previous record of 159 granted in September 2022.
PSNC has heard from hundreds of community pharmacy contractors who are paying inflated prices for antibiotics used for the treatment of Strep A and who have rightly
been concerned about the lack of certainty around the final reimbursement prices for these medicines.
It added: "We welcomed the involvement of the Competition and Markets Authority (CMA) to look into the pricing of antibiotics. But the number of reports we are
getting from contractors about medicines price rises are just not acceptable and this goes far beyond the antibiotic crisis."
As the general election campaign continues, Labour is set to introduce a series of policies aimed at supporting small businesses.
On Saturday, Sir Keir Starmer, alongside shadow chancellor Rachel Reeves and other shadow cabinet ministers, is expected to unveil the party's plans for the sector.
Key proposals include an overhaul of the business rates system to enable high street shops to compete with online giants and ensure access to high street
banking services by accelerating the establishment of banking hubs.
Labour will also commit to addressing the issue of late payment of invoices by requiring large businesses to disclose their payment practices and "revitalise" high
streets by tackling antisocial behaviour.
Sir Keir described small businesses as "the beating heart of driving growth and creating jobs for local people."
The British Generic Manufacturers Association (BGMA) has raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent.
The Department of Health Social Care (DHSC) today announced that the 2019 voluntary scheme payment percentage for 2023 will be 26.5%. The 2019 voluntary scheme
for branded medicines pricing and access is an agreement between the Department of Health and Social Care, NHS England and the Association of the British
Pharmaceutical Industry.
BGMA believes that the high VPAS tax for 2023 risks more medicines shortages, rising prices for the NHS via reduced competition, and new medicine launches to the
UK being deferred.
Mark Samuels, Chief Executive of BGMA, said: "Raising the VPAS tax to 26.5% will damage the UK's medicines supply because it will make some products lossmaking. It
is more than a five-fold tax increase from 2021, and no industry can cope with this unpredictable and exceptional tax volatility.
A change in medication can benefit patients on blood pressure-lowering therapies significantly more than increasing the dose of their current medication.
A recent study from Uppsala University that was published in the Journal of the American Medical Association (JAMA) demonstrates this.
In this study, four different blood pressure-lowering medications were tested out on 280 individuals over the course of a year.
"The effect of a change of medication can be twice as great as the effect of doubling the dose of the patient's current medication. It was clear in our study that
certain patients achieved lower blood pressure from one drug than from another. This effect is large enough to be clinically relevant," said Johan Sundstrom,
cardiologist and Professor of Epidemiology at Uppsala University, who is the first author of the study.
Most Swedes develop high blood pressure sooner or later; more than two million Swedes have high blood pressure at the present time.
Only a fifth of them have managed to bring their blood pressure under control through drug therapy, and some studies suggest that only half of them take their blood
pressure medication as intended.
Could this be because the efficacy and side-effects of the drugs differ from individual to individual?
The government's 200 million dental recovery plan has come under fierce criticism from the opposition party after health minister Dame Andrea Leadsom
admitted that there is a "high likelihood" that it will not deliver 2.5 million dental appointments.
Published last month, the plan is aimed at ensuring easier and faster access to NHS dental care across England, with up to 1.5 million extra treatments expected
to be delivered over the next 12 months. Various new measures were set out to attract new dentists, including increasing dental training places by up to
40 per cent by 2032, as part of the NHS Long Term Workforce Plan.
On Tuesday, Leadsom told MPs on the Health and Social Care Committee that the figure was based on NHS modelling of a "complicated set of factors" and there
is "quite a high likelihood of not being reliable as is the case with all modelling."
Preeti Kaur Gill MP, shadow minister for primary care and public health, expressed shock over the admission by the public health minister that there is
uncertainty regarding the plan's ability to deliver on its promises, which she said: "shows the Conservatives are out of ideas and out of time."
The renowned health and beauty chain has announced impressive annual sales and profit figures, following the expansion of its British high street estate.
According to a report by The Times, Superdrug's pre-tax profits jumped by 43.6 per cent to £111.6 million in the year ending December 2023 compared to the previous
year.
The company's revenue also experienced significant growth, rising by 11.8 per cent to reach £1.52 billion, marking its third consecutive year of market share growth.
Key factors driving this growth include the opening of 14 new stores across strategic locations such as The Trafford Centre in Manchester and Brent Cross shopping
centre in north London, and the refitting of 45 stores last year.
Additionally, the continued expansion of its cheaper, own-label products, along with exclusive launches from brands like Bioré SPF, Nyx X Barbie, and Billie Eilish
fragrances, significantly contributed to a 4.2 per cent year-on-year increase in Superdrug's sales volume.
Stroke is a cerebrovascular syndrome that involves the blockage and bursting of blood vessels in the brain. It shows a multifactorial pattern of inheritance. High cholesterol levels, high blood pressure, hypertension and obesity are the key causes of stroke besides inherited genes.
It is essential for your health to understand high cholesterol symptoms and tips to manage. It becomes more vital when you are above 40. First of all, let's try to understand what is Cholesterol? It is a fat-like substance that is produced by the liver naturally. It has many functions in our body like producing specific hormones, new cell membranes, and Vitamin D.
The NHS Confederation has urged the government to reconsider its 'living with Covid' plan and introduce mitigating actions that will help avoid further
critical incidents being declared at the NHS front-line.
The organisation said the high rates of Covid is having a major impact on the delivery of health services and slowing down efforts to reduce large waiting lists,
noting that the country has been in the grip of another spike in Covid cases resulting from the Omicron BA.2 variant.
With more than 20,000 patients now in hospital with Covid (or who have Covid but are in hospital for other reasons) and high staff absences, NHS is facing huge
operational challenges, harming efforts to reduce waiting times in other areas, it said.
Men can now have their blood pressure checked while visiting a barbershop. The NHS is extending its blood pressure screening services to different local
venues, including barbershops, mosques, and pharmacies. This initiative aims to address the increasing risk of strokes and heart attacks among men.
NHS staff's life-saving actions coincide with recent data indicating that high street pharmacies administered 149,865 blood pressure checks to individuals over
40 in May 2023. This marked a notable increase from the previous year's count of 58,345 in May 2022, the NHS said. "More than 1,300 heart attacks and strokes
could be prevented this year thanks to the high street checks."
"The total number of blood pressure checks delivered by pharmacy teams in the year to March was more than 1 million (1,053,278)," the NHS added.
Furthermore, the government has committed £645 million for a range of added pharmaceutical services. This includes a target of conducting 2.5 million extra blood
pressure checks annually at community pharmacies. This effort is estimated to avert over 1,350 cardiovascular events per year - equivalent to averting 113 heart
attacks and strokes each month.
The widely-held concept that levels of "good" cholesterol in the blood can indicate heart disease risk is not equally true for Blacks and whites, and the measure
itself may be of less value than previously thought, according to a U.S. study published on Monday (November 21).
Various types of cholesterol are thought to have either healthy or unhealthy effects.
Low levels of so-called "good" high-density lipoprotein (HDL) cholesterol were linked with higher odds for developing cardiac problems in the long-term study - but
only in white participants, the study published in the Journal of the American College of Cardiology found.
In contradiction to what has generally been assumed, low HDL levels did not confer any higher risk of heart disease in Black people, researchers said. Among white
people, however, those with HDL levels below 40 milligrams per deciliter had a 22% higher risk for coronary heart disease compared with those whose HDL levels were
higher.
High HDL levels (above 60 mg/dL), which are thought to be protective, were not linked with lower coronary heart disease risks in either race, researchers found.
Digital transformation is sweeping across the healthcare landscape. Fuelled by ambitious government policy, exciting innovation and huge injections of funding,
it's hard for anyone in the sector not to catch a dose of digitisation fever.
But digitisation is not a universal tonic, and it certainly isn't always a 'good thing'. In fact, there's a real danger to digitising healthcare. Such a fundamental
change to the very nature of care delivery is an inevitably high-risk process: sometimes things or people get forgotten, vital processes stall, or new systems fail
to replicate the strengths of those they replace. Take, for instance, the digitisation of pharmacies.
Over recent years, the public's use of online-only pharmacies have boomed: in March it was reported that the number of items dispensed from distance-selling
pharmacies in England, UK quadrupled between 2016 and 2021.
These online providers offer an attractively convenient way for patients to receive their medicines; replacing a trip to a high street pharmacy with a package
delivered straight to their door. On the surface, this digital solution seems perfect not only for young patients with busy schedules, but also for older patients
or for those with restricted mobility who may struggle with in-person collection.